Sophiris surges on BPH data

Sophiris Bio Inc. (NASDAQ:SPHS) rocketed $2.04 (237%) to $2.90 on Tuesday after a single injection of its PORxin topsalysin ( PRX302) met the primary endpoint in the PLUS-1 Phase III trial to treat lower urinary tract symptoms of benign prostatic hyperplasia (BPH).

PRX302 significantly improved International Prostate Symptom Score (IPSS) compared with vehicle over 52 weeks (7.6 vs. 6.58, p=0.043), meeting the 479-patient study's primary endpoint. On secondary endpoints, PRX302 significantly improved self-reported quality of life measures starting at week 18 through week 52 (p=0.004), and non-significantly improved maximum urine flow change from baseline to 52 weeks (p=0.055). ...